Progress of bispecific antibodies for relapsed/refractory multiple myeloma
10.3760/cma.j.cn115356-20240105-00005
- VernacularTitle:双特异性抗体治疗复发难治多发性骨髓瘤研究进展
- Author:
Ketai YAN
1
;
Quande LIN
;
Yongping SONG
Author Information
1. 郑州大学附属肿瘤医院 河南省肿瘤医院血液科 河南省血液病研究所，郑州 450008
- Keywords:
Multiple myeloma;
Antibodies, bispecific;
Immunotherapy
- From:
Journal of Leukemia & Lymphoma
2024;33(2):86-90
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, bispecific antibodies (BsAb), including targeting B cell maturation antigen (BCMA) ×CD3 and G protein-coupled orphan receptor class C group 5 member D (GPRC5D) ×CD3, have been extensively studied for relapsed/refractory multiple myeloma (RRMM) patients. Teclistamab (BCMA×CD3) was the first BsAb approved for RRMM in 2022 by Food and Drug Administration (FDA), and elranatamab was approved in 2023. BsAb targeting BCMA×CD3 including alnuctamab, WVT078, ABBV-383, linvoseltamab, and F182112, as well as talquetamab and LBL-034 targeting GPRC5D×CD3 are currently being evaluated in clinical trials. Combining with the reports in the 65th Annual Meeting of the American Society of Hematology (ASH), this paper reviews the progress of BsAb in treatment of RRMM.
